Category: 41575-94-4

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Partial response of metastatic cardia neuroendocrine carcinoma with the combined therapy involving PD-1 blockade after failed multi-line chemotherapies: a case report and literature review》. Authors are Yang, Yang; Xu, Huan; Zhang, Li; Bai, Liangliang; Zhu, Hong; Li, Qiu.The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).Category: esters-buliding-blocks. Through the article, more information about this compound (cas:41575-94-4) is conveyed.

Cardia neuroendocrine cancer is a rare malignant tumor. The treatment regimens mainly refer to the small-cell lung cancer diagnosis and treatment guidelines and there is no standard treatment guideline specifically for neuroendocrine cancer. The use of albumin paclitaxel plus carboplatin combined with sintilimab for refractory cardia neuroendocrine carcinoma (NEC) has never been reported. This article reported a case that a 68-yr-old man presented with belching without obvious reasons who was diagnosed with refractory cardia NEC by gastroscopy and pathol. results. After failure of multi-line therapy including etoposide plus cisplatin as the first-line therapy, surufatinib plus toripalimab as the second-line therapy, FOLFIRI combined with bevacizumab as the third-line therapy, he received three cycles of albumin paclitaxel plus carboplatin combined with sintilimab as the fourth-line therapy and still obtained partial response of good efficiency. After the patient received this treatment regimen, the symptoms of dysphagia disappeared and the change trends of neuron-specific enolase were decreased. The computed tomog. (CT) examination after three cycles of treatment was performed to show that the measured lesions have shrunk by more than 30% compared to the baseline CT. Addnl., there were no other adverse events such as nausea, vomiting, and diarrhea, except for grade III bone marrow suppression. At present, the patient is still being treated. This is the first case report that the albumin paclitaxel plus carboplatin combined with sintilimab has achieved good efficacy after failure of multi-line treatment of cardia NEC. It is very necessary to further explore the effectiveness and safety of this regimen in the treatment of NEC.

In some applications, this compound(41575-94-4)Category: esters-buliding-blocks is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 41575-94-4, is researched, Molecular C6H12N2O4Pt, about Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients, the main research direction is ovarian fallopian tube primary peritoneal cancer paclitaxel carboplatin; bevacizumab neoadjuvant chemotherapy dose interval debulking surgery; Bevacizumab; Dose-dense TC; Feasibility; Neoadjuvant chemotherapy; Ovarian cancer.Related Products of 41575-94-4.

Abstract: Background: This study aimed to investigate the clin. benefit of dose-dense paclitaxel plus carboplatin (TC) with bevacizumab therapy for advanced ovarian, fallopian tube, and primary peritoneal cancer patients in the neoadjuvant setting. Methods: Ovarian, fallopian tube or primary peritoneal cancer patients with stage III-IV disease received neoadjuvant chemotherapy (NAC) every 3 wk consisting of paclitaxel (80 mg/m2) on days 1, 8, and 15; carboplatin (AUC 6.0 mg/mL x min.) on day 1; and bevacizumab (15 mg/kg) on day 1. Interval debulking surgery (IDS) was performed after 3 cycles of dose-dense TC-bevacizumab therapy. The primary endpoint was the rate of complete resection by IDS. Secondary endpoints were treatment completion rate, treatment exposure, response rate to NAC, adverse events, and perioperative complications. Results: Twenty-four patients were included in this study. The median age was 55.5 years (37-80 years), and most patients had high-grade serous carcinoma accounted (n = 18). IDS was performed in all patients with complete resection achieved in 75‰ (95‰ confidence interval: 57.7-92.3‰). The lower limit exceeded the preset threshold rate of 55‰. The response rate to NAC was 79‰, and serum CA125 levels were in the normal range after NAC in 57‰ of patients. Grade 4 hematol. toxicities and grade 3/4 non-hematol. toxicities occurred in 29‰ and 17‰ of patients during NAC, resp. Grade 3/4 perioperative complications were seen in 29‰ of patients, but no gastrointestinal perforations or treatment-related deaths occurred. Conclusions: Neoadjuvant dose-dense TC-bevacizumab therapy was well tolerated, and a satisfactory rate of complete resection by IDS was achieved.

In some applications, this compound(41575-94-4)Related Products of 41575-94-4 is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)(SMILESS: O=C1C2(CCC2)C(O[Pt]O1)=O.N.N,cas:41575-94-4) is researched.Recommanded Product: 600-05-5. The article 《Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy》 in relation to this compound, is published in Cancer Science. Let’s take a look at the latest research on this compound (cas:41575-94-4).

The utility of Schlafen 11 (SLFN11) expression as a predictive biomarker for platinum-based chemotherapy has been established for cancers from different histologies. However, the therapeutic relevance of SLFN11 in bladder cancer (BC) is unknown. Here, we examined the clinicopathol. significance of SLFN11 expression across 120 BC cases by immunohistochem. We divided the cases into two cohorts, one including 50 patients who received adjuvant or neoadjuvant platinum-based chemotherapy, and the other including 70 BC patients treated by surgical resection without chemotherapy. In the cohort of 50 BC cases treated with platinum-based chemotherapy, the SLFN11-pos. group (n = 25) showed significantly better overall survival than the SLFN11-neg. group (n = 25, P = .012). Schlafen 11 expression correlated significantly with the expression of luminal subtype marker GATA3. Multivariate analyses identified SLFN11 expression as an independent prognostic predictor (odds ratio, 0.32; 95% confidence interval, 0.11-0.91; P = .033). Conversely, in the cohort of 70 BC cases not receiving platinum-based chemotherapy, the SLFN11-pos. group (n = 29) showed significantly worse overall survival than the SLFN11-neg. group (n = 41, P = .034). In vitro analyses using multiple BC cell lines confirmed that SLFN11 KO rendered cells resistant to cisplatin. The epigenetic modifying drugs 5-azacytidine and entinostat restored SLFN11 expression and resensitized cells to cisplatin and carboplatin in SLFN11-neg. BC cell lines. We conclude that SLFN11 is a predictive biomarker for BC patients who undergo platinum-based chemotherapy and that the combination of epigenetic modifiers could rescue refractory BC patients to platinum derivatives by reactivating SLFN11 expression.

When you point to this article, it is believed that you are also very interested in this compound(41575-94-4)Related Products of 41575-94-4 and due to space limitations, I can only present the most important information.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

COA of Formula: C6H12N2O4Pt. Aromatic heterocyclic compounds can also be classified according to the number of heteroatoms contained in the heterocycle: single heteroatom, two heteroatoms, three heteroatoms and four heteroatoms. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about The fetal outcomes after neoadjuvant platinum and paclitaxel chemotherapy during pregnancy: analysis of three cases and review of the literature. Author is Wang, Ming; Yin, Ziran; Miao, Jinwei; Wu, Yumei.

Data on the outcomes of fetus who are exposed to neoadjuvant platinum and paclitaxel chemotherapy during pregnancy are lacking. Relevant data were abstracted from patients in our institution, PubMed, Embase and Cochrane Library databases. The primary assessment was the frequency of fetal death and congenital abnormalities. The secondary assessment was other neg. fetal/infant outcomes including FGR, RDS, secondary malignant diseases and other recorded adverse events. Of the three infants in our center who exposed to platinum and paclitaxel chemotherapy during pregnancy, the phys. evaluation and qualified Denver Developmental Screening Test showed normal findings at the last follow-up (19-24 mo). Hearing evaluation among three children also showed normal findings. Another 34 infants (including a twins) of 21 studies in previous studies who exposed to platinum and paclitaxel chemotherapy during pregnancy were included in the final anal. Of the 37 infants identified, 24 were exposed to cisplatin plus paclitaxel, and 13 were exposed to carboplatin plus paclitaxel. None of the 37 fetuses was abortion or dead during the pregnancy. 97.3% (36/37) infants were delivered by cesareans and the median gestational ages of delivery were 34.76 wk (95% CI, 34.08-35.44). 1 fetus showed intrauterine growth restriction and one was found with left-sided ventriculomegaly and hydramnios before chemotherapy. Adverse events occurred in 18.9% (7/37) infants at birth, including two RDS, one hearing loss, one pathol. jaundice, one first-degree intraventricular hemorrhage, one erythema, one corresponding to -0.5 standard deviation from average body weight of the same gestational weeks. No reports of neonatal cardiol. abnormalities are reported in these infants after the initiating of chemotherapy. The infant with congenital anomaly died 5 days after birth. During the follow-up, 5.4% (2/37) of the infants were diagnosed with malignant diseases. One retroperitoneal embryonal rhabdomyosarcoma at 5 years old and one acute myeloid leukemia at 22 mo of age. 32/37 (86.5%) children were healthy at the end of follow-ups (median 33 mo, IQR 15.75-54.25 mo). Our results showed that neoadjuvant platinum and paclitaxel combined chemotherapy was a feasible and safe choice for the management of patients with cervical and ovarian cancer during the second and third trimesters of gestation.

When you point to this article, it is believed that you are also very interested in this compound(41575-94-4)COA of Formula: C6H12N2O4Pt and due to space limitations, I can only present the most important information.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)(SMILESS: O=C1C2(CCC2)C(O[Pt]O1)=O.N.N,cas:41575-94-4) is researched.Category: benzofurans. The article 《Platinum Doublet plus Atezolizumab as First-line Treatment in Metastatic Large Cell Neuroendocrine Carcinoma: A Single Institution Experience》 in relation to this compound, is published in Cancer Investigation. Let’s take a look at the latest research on this compound (cas:41575-94-4).

Large Cell Neuroendocrine Carcinoma of the Lung (L-LCNEC) is a rare type of neuroendocrine lung cancer that is increasingly diagnosed. However, the optimal management regarding the advanced stage is unclear. The purpose of this article is to present and compare our experience when L-LCNEC is treated as Small Cell Lung Cancer (SCLC). Overall, eight cases of L-LCNEC were included. We retrospectively reviewed medical files and reports by accessing the Institution’s Data of patients diagnosed with L-LCNEC from Apr. 2019 until Dec. 2020 and evaluated their response to the combination of Platinum – Etoposide – Atezolizumab as first-line chemotherapy. The overall observed response rate (ORR) of 75%. The median PFS was 6.85 mo. The median response duration was 5.5 mo. Comparing our findings with other retrospective and prospective studies, it seems that the systematic treatment of choice and management in L-LCNEC of the lung should be that of a small cell carcinoma of the lung.

When you point to this article, it is believed that you are also very interested in this compound(41575-94-4)COA of Formula: C6H12N2O4Pt and due to space limitations, I can only present the most important information.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

HPLC of Formula: 41575-94-4. The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Vinblastine monotherapy induction prior to radiotherapy for patients with intracranial germinoma during the COVID-19 pandemic. Author is Murray, Matthew J.; Moleron, Rafael; Adamski, Jennifer; English, Martin; Burke, G. A. Amos; Cross, Justin; Ajithkumar, Thankamma; Stoneham, Sara; Nicholson, James C..

Patients with localized intracranial germinoma have excellent survival. Reducing treatment burden and long-term sequelae is a priority. Intensive inpatient chemotherapy (e.g., carbo PEI = carboplatin/etoposide/ifosfamide) has been effectively employed to reduce radiotherapy treatment volume/dose. Outpatient-based carboplatin monotherapy is associated with excellent outcomes in metastatic testicular seminoma (an identical pathol.), and successful vinblastine monotherapy induction (with 77% tumor volume reduction after just two weekly vinblastine doses) has recently been reported in an intracranial germinoma patient. Adapted UK guidelines for germ cell tumor management were distributed during the COVID-19 pandemic, including nonstandard treatment options to reduce hospital visits and/or admissions. This included vinblastine monotherapy for intracranial germinoma (6 mg/m2 i.v., or 4 mg/m2 for moderate count suppression, delivered weekly). We describe two such patients treated using this approach. A 30-yr-old male with a localized pineal tumor received 12-wk vinblastine induction, with >60% volume reduction, prior to definitive radiotherapy. A 12-yr-old female with a metastatic suprasellar tumor and progression at all sites of disease while awaiting proton radiotherapy received two vinblastine doses with good early response, including 36% primary tumor volume reduction The patients tolerated vinblastine well. Patients with intracranial germinoma have excellent outcomes, and reduction of late effects remains a priority. The description of vinblastine monotherapy in these intracranial germinoma patients warrants further exploration.

As far as I know, this compound(41575-94-4)HPLC of Formula: 41575-94-4 can be applied in many ways, which is helpful for the development of experiments. Therefore many people are doing relevant researches.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Recommanded Product: 41575-94-4. The fused heterocycle is formed by combining a benzene ring with a single heterocycle, or two or more single heterocycles. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.. Author is Shi, Yang; Chen, Jigang; Shi, Bo; Liu, Aihua.

OBJECTIVE: The effectiveness of pembrolizumab for persistent, recurrent, or metastatic cervical cancer has been demonstrated. We aimed to evaluate its cost-effectiveness from the United States (US) healthcare payers perspective. METHODS: A partitioned survival model over a 30-year lifetime horizon was developed to compare the cost and effectiveness of pembrolizumab versus placebo based on clinical data from the KEYNOTE-826 phase 3 randomized trial. Costs and health state utilities were obtained from literature and publicly available databases. The incremental cost-effectiveness ratio (ICER) was measured. One-way and probabilistic sensitivity analyses were conducted. RESULTS: For the Intention-to-Treat patients, pembrolizumab was associated with an additional 0.74 quality-adjusted life-year (QALY) at an additional cost of $182,271 when compared with placebo. The ICER was $247,663/QALY. For patients with a programmed death-ligand 1 combined positive score ≥ 1 and 10, the ICER was $253,322/QALY and $214,212/QALY, respectively. One-way sensitivity analyses showed that pembrolizumab had the greatest impact on the ICER. Probabilistic sensitivity analyses showed that the probability of pembrolizumab being cost-effective was zero at the current willingness-to-pay threshold of $150,000/QALY. The price of pembrolizumab had to reduce at least to $28.336 (55.8% of the current price) for it to be cost-effective in a 50% of chance. CONCLUSION: The addition of pembrolizumab to chemotherapy is costly and might not be cost-effective for persistent, recurrent, or metastatic cervical cancer at the current price in the US.

This literature about this compound(41575-94-4)Recommanded Product: 41575-94-4has given us a lot of inspiration, and I hope that the research on this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)) can be further advanced. Maybe we can get more compounds in a similar way.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The three-dimensional configuration of the ester heterocycle is basically the same as that of the carbocycle. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)(SMILESS: O=C1C2(CCC2)C(O[Pt]O1)=O.N.N,cas:41575-94-4) is researched.Recommanded Product: (11bS)-4-Hydroxy-2,6-bis(4-nitrophenyl)-8,9,10,11,12,13,14,15-octahydrodinaphtho[2,1-d:1′,2′-f][1,3,2]dioxaphosphepine 4-oxide. The article 《Molecular mechanisms associated with chemoresistance in esophageal cancer》 in relation to this compound, is published in Cellular and Molecular Life Sciences. Let’s take a look at the latest research on this compound (cas:41575-94-4).

Abstract: Esophageal cancer (EC) is one of the most incident and lethal tumors worldwide. Although surgical resection is an important approach in EC treatment, late diagnosis, metastasis and recurrence after surgery have led to the management of adjuvant and neoadjuvant therapies over the past few decades. In this scenario, 5-fluorouracil (5-FU) and cisplatin (CISP), and more recently paclitaxel (PTX) and carboplatin (CBP), have been traditionally used in EC treatment. However, chemoresistance to these agents along EC therapeutic management represents the main obstacle to successfully treat this malignancy. In this sense, despite the fact that most of chemotherapy drugs were discovered several decades ago, in many cases, including EC, they still represent the most affordable and widely employed treatment approach for these tumors. Therefore, this review summarizes the main mechanisms through which the response to the most widely chemotherapeutic agents used in EC treatment is impaired, such as drug metabolism, apoptosis resistance, cancer stem cells (CSCs), cell cycle, autophagy, energetic metabolism deregulation, tumor microenvironment and epigenetic modifications.

Compound(41575-94-4)Product Details of 41575-94-4 received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Sellami, S.; Bourbonne, V.; Hatt, M.; Tixier, F.; Bouzid, D.; Lucia, F.; Pradier, O.; Goasduff, G.; Visvikis, D.; Schick, U. published the article 《Predicting response to radiotherapy of head and neck squamous cell carcinoma using radiomics from cone-beam CT images》. Keywords: head and neck squamous cell carcinoma radiotherapy radiomics human; CBCT; head and neck cancers; radiomics; radiotherapy; texture.They researched the compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)( cas:41575-94-4 ).SDS of cas: 41575-94-4. Aromatic heterocyclic compounds can be divided into two categories: single heterocyclic and fused heterocyclic. In addition, there is a lot of other information about this compound (cas:41575-94-4) here.

Radiotherapy (RT) for head and neck cancer is now guided by cone-beam computed tomog. (CBCT). We aim to identify a CBCT radiomic signature predictive of progression to RT. A cohort of 93 patients was split into training (n = 60) and testing (n = 33) sets. A total of 88 features were extracted from the gross tumor volume (GTV) on each CBCT. Receiver operating characteristic (ROC) curves were used to determine the power of each feature at each week of treatment to predict progression to radio(chemo)therapy. Only features with AUC > 0.65 at each week were pre-selected. Absolute differences were calculated between features from each weekly CBCT and baseline CBCT1 images. The smallest detectable change (C = 1.96 x SD, SD being the standard deviation of differences between feature values calculated on CBCT1 and CBCTn) with its confidence interval (95% confidence interval [CI]) was determined for each feature. The features for which the change was larger than C for at least 5% of patients were then selected. A radiomics-based model was built at the time-point that showed the highest AUC and compared with models relying on clin. variables. Seven features had an AUC > 0.65 at each week, and six exhibited a change larger than the predefined CI 95%. After exclusion of inter-correlated features, only one parameter remains, Coarseness. Among clin. variable, only Hb value was significant. AUC for predicting the treatment response were 0.78 (p = .006), 0.85 (p < .001), and 0.99 (p < .001) for clin., CBCT4-radiomics (Coarseness) and clin. + radiomics based models resp. The mean AUC of this last model on a 5-fold cross-validation was 0.80 (±0.09). On the testing cohort, the best prediction was given by the combined model (balanced accuracy [BAcc] 0.67 , p < .001). We described a feature selection methodol. for delta-radiomics that is able to select reproducible features which are informative due to their change during treatment. A selected delta radiomics feature may improve clin.-based prediction models. Compound(41575-94-4)SDS of cas: 41575-94-4 received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The preparation of ester heterocycles mostly uses heteroatoms as nucleophilic sites, which are achieved by intramolecular substitution or addition reactions. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)( cas:41575-94-4 ) is researched.Electric Literature of C6H12N2O4Pt.Zhang, Liulu; Wu, Zhi-Yong; Li, Jie; Lin, Ying; Liu, Zhenzhen; Cao, Yin; Zhang, Gangling; Gao, Hong-Fei; Yang, Mei; Yang, Ci-Qiu; Zhu, Teng; Cheng, Min-Yi; Ji, Fei; Li, Jieqing; Wang, Kun published the article 《Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative , early-stage breast cancer ( NeoCART ): Results from a multicenter, randomized controlled, open-label phase II trial》 about this compound( cas:41575-94-4 ) in International Journal of Cancer. Keywords: docetaxel carboplatin epirubicin cyclophosphamide triple neg breast cancer; phase II trial; carboplatin; neoadjuvant chemotherapy; triple-negative breast cancer. Let’s learn more about this compound (cas:41575-94-4).

Previous studies have shown that the addition of carboplatin to neoadjuvant chemotherapy improved the pathol. complete response (pCR) rate in patients suffering from triple-neg. breast cancer (TNBC) and patients who obtained a pCR could achieve prolonged event-free survival (EFS) and overall survival (OS). However, no studies have assessed the effects of the combination of docetaxel and carboplatin without anthracycline with taxane-based and anthracycline-based regimens. The NeoCART study was designed as a multicenter, randomized controlled, open-label, phase II trial to assess the efficacy and safety of docetaxel combined with carboplatin in untreated stage II-III TNBC. All eligible patients were randomly assigned, at a 1:1 ratio, to an exptl. docetaxel plus carboplatin (DCb) for six cycles group (DCb group) or an epirubicin plus cyclophosphamide for four cycles followed by docetaxel for four cycles group (EC-D group). PCR (ypT0/is ypN0) was evaluated as the primary outcome. Between 1 Sept. 2016 and 31 Dec. 2019, 93 patients were randomly assigned and 88 patients were evaluated for the primary endpoint (44 patients in each group). In the primary endpoint anal., 27 patients in the DCb group (61.4%, 95% CI 47.0-75.8) and 17 patients in the EC-D group achieved a pCR (38.6%, 95% CI 24.3-53.0; odds ratio 2.52, 95% CI 2.4-43.1; Pnoninferiority = .004). Noninferiority was met, and the DCb regimen was confirmed to be superior to the EC-D regimen (P = .044, superiority margin of 5%). At the end of the 37-mo median follow-up period, OS and EFS rates were equivalent in both groups.

Compound(41575-94-4)Electric Literature of C6H12N2O4Pt received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics